MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar...
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing...
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term...
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -7.245 | -13.5268857356 | 53.56 | 55.01 | 46.3 | 534470 | 50.4923229 | CS |
4 | -7.555 | -14.0245034342 | 53.87 | 58.26 | 46.3 | 291739 | 52.1459413 | CS |
12 | -1.765 | -3.67096505824 | 48.08 | 58.26 | 45.24 | 230288 | 51.12069437 | CS |
26 | 1.325 | 2.94509891087 | 44.99 | 58.26 | 39.36 | 296392 | 49.37712531 | CS |
52 | -12.485 | -21.2329931973 | 58.8 | 64.98 | 37.55 | 350645 | 48.6271828 | CS |
156 | 33.945 | 274.413904608 | 12.37 | 64.98 | 4.25 | 343784 | 43.13745243 | CS |
260 | 33.945 | 274.413904608 | 12.37 | 64.98 | 4.25 | 343784 | 43.13745243 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約